Sarepta Secures FDA Nod For Elevidys Study To Reduce Liver Injury Risk

The FDA cleared dosing for Cohort 8 of Sarepta’s ENDEAVOR (SRP-9001-103) trial to evaluate peri-infusion and 12-week post-infusion sirolimus as an enhanced immunosuppressive regimen to reduce acute liver injury (ALI) in ~25 non-ambulant Duchenne patients; primary endpoints are incidence of ALI and Elevidys-dystrophin expression at 12 weeks. The program follows three reported fatalities linked to acute liver failure in patients receiving Elevidys or AAVrh74-platform therapies and comes as the study has enrolled 55 participants across seven cohorts; separately Sarepta reported progress in the SRP-1003 MAD study (cohorts 1–3 complete, cohort 4 dosing) and that a milestone triggered a $200 million payment to Arrowhead. SRPT shares were up ~1.9% at $19.27 at publication.

Analysis

Market structure: Short-term winners are Arrowhead (ARWR) from a $200M milestone payment and cash runway relief, and suppliers/adjuncts to immunosuppression protocols; losers are AAV-dependent small-caps and Sarepta (SRPT) which face persistent safety overhang that constrains uptake and pricing power for Elevidys. The Elevidys label and payer willingness remain the demand anchor — any sustained ALI signal will compress willingness to pay and could reduce peak sales by >30% vs base-case projections over 3–5 years.

Risk assessment: Primary tail risk is regulatory/clinical (another ALI fatality or FDA clinical hold) that could vaporize >50% of SRPT market cap within days; secondary tails are multi-hundred-million litigation settlements and manufacturing holds. Near-term (days–weeks) expect volatility around enrollment/dosing updates; intermediate (3–12 months) hinge on 12-week expression/ALI readouts from Cohort 8; long-term (1–3 years) outcome determines AAV platform adoption and partner economics.

Trade implications: Tactical trades should be asymmetric and time-boxed — protect/short SRPT rather than naked short equity; selectively long ARWR to capture milestone de-risking. Options volatility is likely elevated on SRPT; favor defined-risk put spreads and calendar spreads to exploit event-driven IV skew. Rotate exposure away from AAV-only small caps into RNAi/non-viral vectors where clinical risk is more linear.

Contrarian view: Consensus underweights the binary benefit that an effective sirolimus regimen could materially restore commercial viability — if Cohort 8 shows ALI incidence ≤10% at 12 weeks, re-rating could be >+50% for SRPT from current levels over 6–12 months. Conversely the market may be underpricing litigation and platform stigma; immunosuppression fixes can create new morbidity (infections) that reinscribe payer resistance. Treat any position as binary-event exposure and size accordingly.

Key Decisions for Investors

• Establish a defined-risk short in SRPT equal to 2% of portfolio via a 90-day put spread (buy SRPT 17.5/12.5 put spread) sized to lose no more than ~0.5% if spread widens; cover/trim if SRPT falls >30% or if Cohort 8 ALI incidence ≤10% at 12-week readout.
• Add a 1–1.5% long in ARWR via 6–9 month at-the-money call options (or equity) to capture the $200M milestone de-risk; target +40% upside, stop-loss -30% from entry, reassess on next 60-day cash/milestone update.
• Implement a 1:1 pair trade: long ARWR (1% portfolio) vs short SRPT equity (1%) to express divergence between milestone-funded RNAi vs AAV safety risk; rebalance after Cohort 8 enrollment completes or at the 12-week endpoint.
• Reduce aggregate exposure to AAV-platform small-cap biotech by 20% in the next 30 days; redeploy into non-viral/siRNA names and larger-cap gene therapy companies with diversified platforms to lower binary regulatory risk.